(AOF) – Predilife (specialist in innovative pathology risk prediction solutions for personalized medicine) announces the launch of Mammorisk tests at the Veneto Institute of Oncology. Located in Padua, this institute is the Veneto Regional Government’s Cancer Center. Wishing to offer a complete course from prevention to treatment, the IOV launched a call for tenders of which Predilife was the winner. The Venetian institute will now open a breast cancer risk prediction consultation based on this solution.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.